NASDAQ · INVA
Healthcare · Biotechnology
$19.08
Down-$0.40 (-2.07%)
Updated Nov 11, 2026, 4:03 PM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · INVA
1M range · 0 trading sessions · Daily adjusted prices
INVA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning INVA.
Company
Market Activity
Research & News
INVA research
Company profile and research snapshot.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 5, 2026 | Oppenheimer | Outperform | — |
| Aug 7, 2026 | Cantor Fitzgerald | Overweight | — |
| Jun 22, 2026 | BTIG | Buy | — |
| Jun 1, 2026 | HC Wainwright & Co. | Buy | — |
| May 26, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Yahoo · Nov 10, 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Benzinga · Nov 5, 2026
Oppenheimer analyst Les Sulewski maintains Innoviva (NASDAQ:INVA) with a Outperform and lowers the price target from $35 to $34.
Yahoo · Nov 4, 2026
Innoviva (INVA) delivered earnings and revenue surprises of +2.04% and -6.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Nov 4, 2026
(INVA) on Wednesday reported a loss of $73.On a per-share basis, the Burlingame, California-based company said it had a loss of $1.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INVA.
